MedPath

To evaluate the efficacy and the safety profile of Rhubarb and alpha-Keto amino acid supplementation on patients of Chronic kidney disease.

Phase 4
Completed
Conditions
Health Condition 1: null- Chronic kidney disease
Registration Number
CTRI/2012/09/002947
Lead Sponsor
Department Of Pharmacology And Department Of Medicine
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
Not specified
Target Recruitment
100
Inclusion Criteria

•Chronic kidney disease of different etiology, before ESRD.

•Patient not on dialysis.

Exclusion Criteria

•Pregnancy

•Acute infection

•Psychotic patient

•Critically ill patient

•HIV/HBsAg/Anti-HCV and immunocompromised patient.

•Severe Renal pathology such as malignancy

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1.Haemogram <br/ ><br>2.Urine- Routine & Microscopic <br/ ><br>3.Blood Glucose <br/ ><br>4.Total Urine Protein(TUP) <br/ ><br>5.Blood Urea <br/ ><br>6.Serum Creatinine <br/ ><br>7.Urine Creatinine <br/ ><br>Timepoint: Pre-dose and after 1st 2nd 3rd month after starting dosing
Secondary Outcome Measures
NameTimeMethod
1.USG-Both kidneys <br/ ><br>2.Chest X-ray( PA VIEW) <br/ ><br>Timepoint: Pre-dose and after 3 month post-dose.
© Copyright 2025. All Rights Reserved by MedPath